Anthem Biosciences, a Bangalore-based pharmaceutical company, opens its IPO tomorrow for subscription. The company is focused on contract research, development, and manufacturing. The initial public offering (IPO) of Anthem Biosciences is set at a price band of ₹540–₹570, with a minimum investment of ₹14,040 for 26 shares. The maximum lot allowed for bidding is 13 lots.
The major promoters of the company are Ajay Bhardwaj, holding 42.53%; Ganesh Sambasivam, holding 9.23%; K. Ravindra Chandrappa, holding 8.86%; Ishaan Bhardwaj, holding 10.16%; and Krithika Ganesh, holding 1.52% of shares.
The company will open bidding on July 14, 2025, and will close it on July 16, 2025. The allotment date for the shares is set for July 17, 2025. The issue size for the Anthem Biosciences IPO is ₹3,395 crore.
About Anthem Biosciences
Anthem Biosciences was founded in 2006. The company is headquartered in Bangalore. Anthem Biosciences Limited is driven by innovation and technology, focused on contract research, development, and manufacturing. The company operates in drug discovery, development, and manufacturing.
It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities.
Anthem Biosciences’ clients include innovation-focused emerging biotech and large pharmaceutical companies that operate globally.
(Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Before making any investment, conduct thorough research and consult a financial advisor).
Also Read: A New Market Link: NSE GIFT City And Cyprus Stock Exchange Sign MoU
Ankur Mishra is a journalist who covers an extensive range of news, from business, stock markets, IPOs to geopolitics, world affairs, international crises, and general news. With over a decade of experience in the business domain, Ankur has been associated with some of the reputed media brands. Through a sharp eye on global marketplaces along with deep insights and analysis of business strategies, Ankur brings simplicity to the complex economic matrix to decode market trends and empower people.
He is committed to entrenched data, facts, research, solutions, and a dedication to value-based journalism. He has covered trade tariff wars, international alliances, corporate policies, government initiatives, regulatory developments, along with micro- and macroeconomic shifts impacting global fiscal dynamics.
